JP2025509730A5 - - Google Patents

Info

Publication number
JP2025509730A5
JP2025509730A5 JP2024555107A JP2024555107A JP2025509730A5 JP 2025509730 A5 JP2025509730 A5 JP 2025509730A5 JP 2024555107 A JP2024555107 A JP 2024555107A JP 2024555107 A JP2024555107 A JP 2024555107A JP 2025509730 A5 JP2025509730 A5 JP 2025509730A5
Authority
JP
Japan
Application number
JP2024555107A
Other languages
Japanese (ja)
Other versions
JPWO2023178202A5 (https=
JP2025509730A (ja
Filing date
Publication date
Priority claimed from US17/695,645 external-priority patent/US12485178B2/en
Application filed filed Critical
Priority claimed from PCT/US2023/064470 external-priority patent/WO2023178202A2/en
Publication of JP2025509730A publication Critical patent/JP2025509730A/ja
Publication of JP2025509730A5 publication Critical patent/JP2025509730A5/ja
Publication of JPWO2023178202A5 publication Critical patent/JPWO2023178202A5/ja
Pending legal-status Critical Current

Links

JP2024555107A 2022-03-15 2023-03-15 循環タンパク質の選択的分解を目的とした二官能性小分子 Pending JP2025509730A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/695,645 2022-03-15
US17/695,645 US12485178B2 (en) 2018-04-09 2022-03-15 Bifunctional small molecules to target the selective degradation of circulating proteins
PCT/US2023/064470 WO2023178202A2 (en) 2022-03-15 2023-03-15 Bifunctional small molecules to target the selective degradation of circulating proteins

Publications (3)

Publication Number Publication Date
JP2025509730A JP2025509730A (ja) 2025-04-11
JP2025509730A5 true JP2025509730A5 (https=) 2026-03-24
JPWO2023178202A5 JPWO2023178202A5 (https=) 2026-03-24

Family

ID=88024440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024555107A Pending JP2025509730A (ja) 2022-03-15 2023-03-15 循環タンパク質の選択的分解を目的とした二官能性小分子

Country Status (8)

Country Link
EP (1) EP4493222A2 (https=)
JP (1) JP2025509730A (https=)
KR (1) KR20240166514A (https=)
CN (1) CN119255822A (https=)
AU (1) AU2023236291A1 (https=)
IL (1) IL315579A (https=)
MX (1) MX2024011338A (https=)
WO (1) WO2023178202A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022310356A1 (en) 2021-07-14 2024-01-25 Lycia Therapeutics, Inc. Asgpr cell surface receptor binding compounds and conjugates
WO2025219911A1 (en) * 2024-04-16 2025-10-23 Biohaven Therapeutics Ltd. Treatment of diseases with monoclonal antibody drugs and molecular degraders
WO2025248469A1 (en) * 2024-05-28 2025-12-04 Biohaven Therapeutics Ltd. TREATMENT OF IgG-RELATED DISEASES

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2997444A1 (en) * 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
US12364766B2 (en) * 2018-04-09 2025-07-22 Yale University Bifunctional small molecules to target the selective degradation of circulating proteins
WO2019199621A1 (en) * 2018-04-09 2019-10-17 Yale University Bi-functional molecules to degrade circulating proteins
CN113301925A (zh) * 2018-12-19 2021-08-24 小利兰·斯坦福大学理事会 用于溶酶体靶向的双官能分子以及相关的组合物和方法
IL294515A (en) * 2020-01-31 2022-09-01 Avilar Therapeutics Inc Compounds bind asgpr to degrade extracellular proteins

Similar Documents

Publication Publication Date Title
JP2022087358A5 (https=)
JP2025509730A5 (https=)
BR102022025291A2 (https=)
CL2025004051A1 (es) Compuestos derivados de beta-carbolina y uso para inhibir la dihidroorotato deshidrogenasa.
CL2025003270A1 (es) Composición antiparasitaria controlar infecciones parasitarias en colmenas
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR102022023461A2 (https=)
BY13164U (https=)
BY13158U (https=)
BY23963C1 (https=)
BY13176U (https=)
BY13175U (https=)
BY13174U (https=)
BY13172U (https=)
BY13170U (https=)
BY13169U (https=)
BY13168U (https=)
BY13167U (https=)
BY13166U (https=)
BY13165U (https=)
CN307044206S (https=)